Skip to main content

Table 4 Correlation between clinico-pathological features and the expressions of Hsp90-beta and annexin A1 in lung cancer

From: Upregulation of Hsp90-beta and annexin A1 correlates with poor survival and lymphatic metastasis in lung cancer patients

Parameter

Group

N

Expression of Hsp90-beta

Expression of annexin A1

Low (%)

Moderate (%)

High (%)

χ2value

P value

Low (%)

Moderate (%)

High (%)

χ2value

P value

Gender

            
 

Male

73

12(16.4)

22(30.1)

39(53.4)

4.49

0.105

18(24.7)

26(35.6)

29(39.7)

5.09

0.078

 

Female

23

2(8.7)

3(13)

18(78.3)

2(8.7)

6(26.1)

15(65.2)

Ages

            
 

<60

54

8(14.8)

13(24.1)

33(61.1)

0.251

0.882

8(14.8)

20(37)

26(48.1)

2.798

0.247

 

≥60

42

6(14.3)

12(28.6)

24(57.1)

12(28.6)

12(28.6)

18(42.9)

Smoking

            
 

0

37

3(8.1)

6(16.2)

28(75.7)

8.28

0.082

5(13.5)

10(27)

22(59.5)

3.856

0.248

 

0.1–40

12

1(8.33)

5(41.67)

6(50)

2(16.7)

5(41.7)

5(41.7)

 

>40

47

10(21.3)

14(29.8)

23(48.9)

13(27.7)

17(36.2)

17(36.2)

Histology

            
 

LAC

39

8(20.5)

9(23.1)

22(56.4)

8.16

<0.05

7(17.9)

9(23.1)

23(59)

7.513

<0.05

 

LSCC

41

5(12.2)

13(31.7)

23(56.1)

10(24.4)

19(46.3)

12(29.3)

 

SCLC

11

1(9.1)

1(9.1)

9(81.82)

2(18.2)

2(18.2)

7(63.6)

 

Others

5

0(0)

2(40)

3(60)

1(20)

2(40)

2(40)

Pathological grade

            
 

Poorly

26

1(3.8)

4(15.4)

21(80.8)

31.26

<0.0005

2(7.7)

2(7.7)

22(84.6)

38.26

<0.0005

 

Moderately

33

1(3.03)

12(36.36)

20(60.61)

5(15.2)

21(63.6)

7(21.2)

 

Well

22

11(50)

6(27.3)

5(22.7)

10(45.5)

5(22.7)

7(31.8)

 

Undifferentiated

15

1(6.67)

3(20)

11(73.33)

3(20)

4(26.7)

8(53.3)

Lymphatic invasion

            
 

N0

41

12(29.3)

18(43.9)

11(26.8)

31.02

<0.0005

17(41.5)

13(31.7)

11(26.8)

19.97

<0.0005

 

N1

40

1(2.5)

5(12.5)

34(85)

2(5.5)

17(34.5)

21(60)

 

N2

11

0(0)

2(18.2)

9(81.8)

1(9.1)

1(9.1)

9(81.82)

 

N3

4

0(0)

0(0)

4(100)

0(0)

0(0)

4(100)

hydrothorax

            
 

Absent

82

13(15.9)

23(28)

46(56.1)

2.51

0.285

18(22)

29(35.4)

35(42.7)

2.25

0.324

 

Present

14

1(7.1)

2(14.3)

11(78.6)

2(14.3)

3(21.4)

9(64.3)

T stage

            
 

T1 – T2

57

11(19.3)

22(38.6)

24(42.1)

14.72

0.001

17(29.8)

23(40.4)

17(29.8)

14.83

0.001

 

T3 – T4

28

2(7.1)

2(7.1)

24(85.7)

1(3.6)

7(25)

20(71.4)

 

Unavailable

11

1(9.1)

1(9.1)

9(81.82)

2(18.18)

2(18.18)

7(63.64)

pTNM

            
 

IB

3

1(33.3)

2(66.7)

0(0)

11.449

0.022

0(0)

3(100)

0(0)

9.97

0.008

 

IIA-IIB

53

10(18.9)

19(35.8)

24(45.3)

16(30.2)

20(37.7)

17(32.1)

 

IIIA-IIIB

25

2(8)

3(12)

20(82)

2(8)

6(24)

17(68)

 

IV

4

0(0)

0(0)

4(100)

0(0)

1(25)

3(75)

 

Unavailable

11

1(9.1)

1(9.1)

9(81.82)

2(18.18)

2(18.18)

7(63.64)

Imaging

            
 

Central

43

5(11.63)

15(34.88)

23(53.49)

2.68

0.261

11(20.9)

16(41.9)

16(37.2)

2.07

0.356

 

Ambient

49

9(18.37)

10(24.49)

30(57.14)

8(20.4)

16(32.7)

25(46.9)

 

Unavailable

4

0(0)

0(0)

4(100)

  

1(25)

0(0)

3(75)

  
  1. p < 0.05, SCLC compared with LSCC and LAC, respectively; p < 0.05, LSCC compared with LAC and SCLC, respectively; p<0.0005, N0 compared with N1, N2, and N3, respectively; p<0.0005, N0 compared with N1, N2, and N3, respectively; p = 0.022, IB and IIA-IIB compared with IIIA-IIIB and IV, respectively; p = 0.022, IB and IIA-IIB compared with IIIA-IIIB and IV, respectively; LAC, lung adenocarcinoma; LSCC, lung squamous cell carcinoma; SCLC, small cell lung cancer; LCLC, large cell lung cancer; Smoking, pack years of smoking.